Thesis: AMNOG makes the further development of drugs more difficult

07.02.2014 16:38

The inaugural lecture by Dr. Dagmar Braun at Fresenius University.

The Hessian Ministry of Science and Art appointed the doctor, who has a doctorate, to the position of professor in the Department of Economics & Media. The inaugural lecture “The Impact of German Benefit Assessment on R&D and Life-Cycle Management of Medicines” will traditionally be held publicly on February 11th at 4 p.m. at the Fresenius University of Applied Sciences (Limburger Straße 2, 65510 Idstein, House A, Room 1.01). Those interested are invited to attend the inaugural lecture. They are asked to register by email ([email protected]).

Since completing her medical studies, Dr. Dagmar Braun works in teaching. She received the Federal Cross of Merit for the development of the East and her sustainable association work in Mecklenburg-Western Pomerania. Dagmar Braun has been an active faculty member at Cardiff University and the Department of Business & Media at Fresenius University for five years. There she teaches as a lecturer in the cooperative master's program International Pharmacoeconomics & Health Economics (M.Sc.) and has contributed to its development and progress. In her inaugural lecture, Dagmar Braun critically examines the law to reorganize the pharmaceutical market (AMNOG), which came into force in January 2011, and whose essential component is the early benefit assessment of new drugs. In Dagmar Braun's opinion, the law therefore has a significant influence on the further development of medicines and hinders research in this area.